<SEC-DOCUMENT>0001213900-20-015376.txt : 20200619
<SEC-HEADER>0001213900-20-015376.hdr.sgml : 20200619
<ACCEPTANCE-DATETIME>20200619172032
ACCESSION NUMBER:		0001213900-20-015376
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200619
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200619
DATE AS OF CHANGE:		20200619

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		20976558

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea123229-8k_actinium.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;13 OR 15(d)
of the</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event
reported): June 19, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>001-36374</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction<BR>
of incorporation)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(IRS Employer<BR>
Identification No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>275 Madison Avenue, 7<SUP>th</SUP>
Floor, New York, NY 10016</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of Principal Executive Offices)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number:
(646) 677-3870</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(<U>see</U>&nbsp;General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD><FONT STYLE="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock, par value $0.001 per share</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>ATNM</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>NYSE American</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: right; text-indent: 0.5in">Emerging growth
company&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 19, 2020, Actinium Pharmaceuticals,
Inc. (the &ldquo;Company&rdquo;) issued a press release announcing the closing of the previously reported public offering of its
common stock (or pre-funded warrants to purchase common stock in lieu thereof). A copy of the press release is attached as Exhibit
99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea123229ex99-1_actinium.htm"><FONT STYLE="font-size: 10pt">Press Release, dated June 19, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><B>Actinium Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: &nbsp;June 19, 2020</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><I>/s/ Sandesh Seth</I></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Sandesh Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea123229ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE, DATED JUNE 19, 2020
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. Announces Closing of $25.0 Million Public Offering </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK, NY &ndash; June 19, 2020 &ndash; <B>Actinium Pharmaceuticals, Inc.</B> (NYSE AMERICAN: ATNM) (&ldquo;Actinium&rdquo; or
&ldquo;the Company&rdquo;) today announced the closing of its previously announced public offering of 76,923,077 shares of its
common stock (or common stock equivalents in lieu thereof) at a price to the public of $0.325 per share of common stock (or common
stock equivalent). The aggregate gross proceeds from this offering are approximately $25.0 million, before deducting placement
agent fees and other estimated offering expenses payable by Actinium.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as exclusive lead placement agent for the offering. Maxim Group LLC and JonesTrading Institutional
Services LLC acted as co-placement agents for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actinium
intends to use the net proceeds from the offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate,
Iomab-B, prepare and submit a Biologics License Application (&ldquo;BLA&rdquo;) to the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
and Marketing Authorization Application (&ldquo;MAA&rdquo;) to the European Medicines Agency (&ldquo;EMA&rdquo;) as well as commercialization
activities for Iomab-B in the United States. Net proceeds from this offering will also be used to progress Phase 1 trials for
its refocused CD33 program to the proof of concept stage, to support its AWE Technology Platform, Iomab-ACT program, research
and development and for general working capital needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed
with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and was declared effective on October 12, 2017. The offering was
made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary
prospectus supplement describing the terms of the offering was filed with the SEC on June 16, 2020 and is available on the SEC&rsquo;s
website at&nbsp;www.sec.gov. The final prospectus supplement, dated June 16,
2020, and accompanying prospectus relating to the offering was filed with the SEC on June 18, 2020 and is available on the SEC&rsquo;s
website at http://www.sec.gov.
Electronic copies of the final prospectus supplement and the accompanying base prospectus relating to the offering may also be
obtained from H.C. Wainwright &amp; Co., LLC, 430 Park Avenue 3rd Floor, New York, NY 10022, by telephone: (646) 975-6996 or by
e-mail: placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine
the targeting ability of antibodies with the cell killing ability of radiation. Actinium&rsquo;s lead application for our ARCs is targeted
conditioning, which is intended to selectively kill patient&rsquo;s cancer cells and certain immune cells prior to a BMT or Bone Marrow
Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities.
With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating
or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Our lead product candidate,
Iomab-B is being studied in the ongoing pivotal Phase 3 <B>S</B>tudy of <B>I</B>omab-B in <B>E</B>lderly <B>R</B>elapsed or <B>R</B>efractory
<B>A</B>cute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SIERRA trial is over fifty percent enrolled and promising
single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Beyond Iomab-B, we
are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted
conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with
a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Underpinning
our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform. This is where our intellectual property
portfolio of over 120 patents, know-how, collective research and expertise in the field are being leveraged to construct and study
novel ARCs and ARC combinations to bolster our pipeline for strategic purposes. Our AWE technology platform is currently being
utilized in a collaborative research partnership with Astellas Pharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain projections or other &ldquo;forward-looking statements&rdquo; within the meaning of the &ldquo;safe-harbor&rdquo;
provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance
of the Company which the Company undertakes no obligation to update, including but not limited to, statements relating to the
Company&rsquo;s expectations regarding the intended use of proceeds of the public offering. These statements are based on management&rsquo;s
current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated
or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final
results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental
agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium&rsquo;s products
and services, performance of clinical research organizations and other risks detailed from time to time in Actinium&rsquo;s filings
with the SEC, including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q
and Forms 8-K, each as amended and supplemented from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Investors:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Hans
Vitzthum<BR>
LifeSci Advisors, LLC<BR>
Hans@LifeSciAdvisors.com&nbsp;<BR>
(617) 535-7743</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "" @@# 2(  A$! Q$!_\0
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M5V*3>:\*\R [LNA!!8/U/48'85]A6EI;6-O%:VD,=O;0((XH8E"(BJ %"J
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M2YS@*,\YZ?+GL*_-K]F"%9O^"O'[2+.N1#;?%AU.>A?4_!D)/7G*2NHZX!X
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M%A\3@Z>%R]JM2J4,ROA70[SX8?\ !43X(^-;/QAI_C'POX^^&7Q)\'3+:/\
M"C5-%FU[QGXIU5[S^SD\/^"=.TB(7FN>)5U$QV=UH5S8Z7?6(<WUS&FEPW5]
M;Y%S_P %.=$\%?$7PYX)^.W[//QB^ ND>+I(AH/BSQU!IC0?99[I+--2U33+
M%V:VT^WN)84U272[_6Y]($J27UO''EJ^4?AO!;?\/IOB"(X(D5;;Q5.0T<;$
M7#_"G0A-<Q'9F.:1IG)E7$F'E4L1*P/:_P#!;FTB/PI^"%YY2&6+Q]XHM4E(
M7S4BO/!US-+ AQN$4SV,$DB@[2\$18':N/O,/X?>&M?Q*X'X+_U9S.& \2^$
M<CX@CBGQ3F4\3PGC,^X>S',*6'R:*P4*>98?!XW+92E+B!XFKB*-=8>*HPHN
MM5_*<;XP>-V$\%?%KQ(?'&23S;P,\1.*.$7@X\"Y-' ^(&7<*\4Y'E];%<1S
MGF$Z^3XO'Y5GD,/"GPG' 8?#8O"2QLYUI5UAZ7[<QS)*D<D3I(DBH\<D;!XY
M(W 9)(V4D,C(0RN"0001D'-2UP/PN$G_  K;X=/.SM<-X$\'^:78NQD/A_3_
M #68Y.YBP)9LG).23UKOJ_E/$T?J^)Q6&YN?ZMBL3A^>UE/ZOB<1AU.*UM&:
MH*:5W;G:N[)G]_9=BGCLOP&.</9/&X# 8WV?,Y>S>-P&"QCI<S2YO92Q<J7-
M9<RIJ5DY-(HHHK$[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /Y<?VWOVC[WX1_P#!2+XQ>&?%&FCQC\-=5\-?"%Y=#O&F
MNI?#.H3> M,WZSX=A9S%''.Q#ZQI:*D5^H^UQ&.]C+3K_P -1_LY@_/HGA9R
M"1N;1]38\=?^7,#VQ@'Z]:_0K]J;_@E=IG[1'QZ\;_'\?$RZTO6/&.F^$=)7
MP^VAQ26VDVWA7PY9:$/)OS>AYY;]K5KN9FMHS$)%MTRB-(_SW_PY6GR,_%)C
MGIC2@.G/:;\?Y<<5_:G"G'G@OA>">%L)FV;0IY[@\BP.$S'#PRW.%3IXNA3K
M0J1J5*&$="K5NX<]6E.<*FDG.33D?Y'>)?T;O'GB'QFX_P"*,EX6S*7#V<<5
MYIF&5XVGQ=EV%I8S!8BIA94:\,#+B2C5PT7[.JE3JX6A-V;=%=?!8OVK_P!G
M*%=J:#X6"\?=T74!GD9/_'H2#CL>G/-+)^UG^S>P"R^&/"$JYSB70M0=>,9R
MC614\=L'/3GH?=S_ ,$5;CG'Q2.2.ITA".3R"/M'UZ''UZ5^<?\ P4L_9E\-
M?\$W_@OX<^+GBG5]0^(\WBSXAZ%\/-#\-6$T'ATR7FJ:?JVL7VI7.IR6VJ+#
M!IFF:+=R"%;5WN[B2"$/&K.Z^!C^+.!\YQE++N&\10Q&,Q=1TL-2C@L73G5G
M-M02GBJ,5%M_:E.*TT=S]<X.\&?%#AZA&MGN3X_#4J,8.K.KQ!@\5%*Z;O&E
MG&(E*RT:Y;=$G>S^A=1_:1_9.U3:VH?#WX=7+(0RM)X0D+ @Y^__ &7D9(!Q
MG&?RIES^U=^S38V:V]CX5\'6<*+M6*WT&_A1<'(VB.Q4 =,'VP#P*_ -/VS_
M (2ROX7,/P_\1W$.L:KI-AK?V?Q=:O-H5K?:G!8WEU;Q'PW_ ,32:QM9I+V.
MV#6_VHQK;"5'?S%_IZC_ ."*1UBQM;RW^*SBWNX8[F%_[&4LT,Z"2)BAN P+
M(RDJ3\I)SR,5^/\ B!E.9Y/B,)+-<-4P\,9[66%E.=.K&K"BU&=G2J55'E<X
MKEDT]=M++^OO#W#2AAZE-*TZ,(J:YO>CS.+C>^NO*U>[VOJFCXI\0_M=?L]D
M,1HGAM>H^73-77Z8"VYR??'!KP?Q'^UQ^S^?,(TK0U)4\K9ZZIZGLL2X'8#/
M;C/;]*M1_P""#=Q?YQ\9/+W8//A]7QCV^VCM^'?&:X+4O^#>6YU#<?\ A>YB
M!XP/"P?W_P"@D.O X./;T^=R[-LOH<OMJL8O1R4J,I[K5?PVGKN[M.US[O%X
M3$U>;V4)/32TDM6]6KRCK;L[L_)GQ'^UY\"0K(EKI2#GA8_$"GJ>RQYZ>X/T
MYKP/Q)^UW\$,OMCLU(SC;)XH3C..-K#'?'0$?3-?M-J7_!MA<:CNQ^T.8@Q.
M/^*/\S'7'75EZ="?P!Z5P>H_\&O5Q?DC_AIGR@1SGP.&(]3_ ,AP9Y]N>]?H
MN5<9\-8;E]OC*$;-7_V"I)=-7_LCO9=+.^UCYG%Y'FE3FY*,VWLEB(+1[K^*
ME^7J?@]XA_:_^#&'Q+&O##"W7BI>.F,AQD^_6OA[]HS]K^SU#PS>>'_A5]LL
M=1U.,Q7WBVWU?Q##/I%HS$-!HR3WT;+JEPI*G4&CQ8PDFWW7;"2'^HG4?^#4
M::_W8_:I,>>,?\*^W@<'&,:\._<<$8X'?S[5?^#0^[U*.9(OVO6M'D1@)/\
MA6H?8QY1@I\2KO"L =K;<@X!!PP_0,O\3. J,)QK9GADY0E'7**KYG*,HVYO
M[,:7Q+K;NT?+XGA/B*I44Z>%K-J<7=XRDDE&47_T%K:S:TZ65W8_I0_X)DZW
MJNM_ K1;C5;^ZU"9=&T%1+=RO/*?^)-8<M+(S.['^)F8L3EF)))/Z2RQI-&\
M4BATD4HRMR&4C!!ZU\P_LK_L_']GGX?V/@MM3.JFRLM/LC=[/*$QL;*WM#*8
M=[^493!Y@3>^P/LW-M#'ZAK^29M2G.2=TYS<7KJG*33ULU=2O9I-;61^T17N
MI-*W*E;HK)*VRT6W;332Q^0G[5/_  2F^ GQI\<S_%U_!WAP>,GC1;S5I-&M
M&U*Z@@_U4-U=1I&]ZD2LR0&]$YMU(2(J@"C@O!OPYL/@C96OAS0;5;&QTWRH
M=D,2P);F'"(\4<:HB6_"JT:*%CX=0 9#7[:R1K*C(X!5A@@C(KXZ^/O@/2[*
MSN_$?R0PVL,]W=A%&\P01O-,54$[F\M&PAX+$+QS7[!X=\95*=6ED6:U*F(P
MTU*E@W5J5:JHJ2M[&$)SG""EHO<A%/KU/RCQ#X6EB<-+-LO;I5</:I5IPY8J
M;3O[162NU]I.^EFK;&?X,^-WV3PY-:7C.]Q##A'P6Q\N S, >.A#9P?K7S1X
MU\17OC'5+F*1FE6YW+("00D$AVG Q]^1250$= TA VU_'/K/_!4GQ_\ %#QM
M\2O%FM^,_'?AFT;4M5B^$GA7P=XJUKPYH_@?2M/U&:UT98[;1[JTAU/5YM/C
M2[UK5=<34);V_DEB58K%8+2'^DW_ ((^_'/Q!^V?\#+7QA\01')XX\&^-=<\
M ^*-76&WM8_%DFC1:;J.E^)FM+>.&VMKV^T;5K*#5K>UBCM?[3M+J>WCCCN/
M*C_8J_"^4<'X;&<41C1DL5!U*L:2G+ZO.<.>%/6"BW/WHR4+*$TXN\6I'YYC
M9\29U1RO)\36C*G3G3HRA&?+).2]WGE>\TMN9-6O?0]7\-?\$E_@5\4/B _Q
M5\2>"O#C:E?30W-_<W&B6C76H&';M-]+L5+UP@""6\BGE*A4+LJA1^VG@;P3
MH?P^\-:9X6\/6D5GI>E6L%I;0PQK%&D4$:Q1HD<:I&B(B*B(BJB(%0* HK8T
M;2[?2;*"TMXU1(XE&%  /"]2.N3DX/\ A6O7\O<3<1XSB+'2K5Z]66%HSJ+!
MX:56I.C0@Y._LZ<ZDH4W*RYO9P@GMJM#]^X>R6CDN7T,/%*5;V4%7K22]I4E
M%;.2^RNBO;K9.X5"[.&P.AYSZ8QD=P 03[YY'K4U&!Z"OG/^#^/7U6ZZ7/>]
M/\S\Z_&_[#7CCX@_%#PQ\8=>_:Y^+(\;^ [K59_A]<V7A#X:V>E^#;?5O,CO
M+33=$3P__9MT+JRD73[^ZU."\N]1MHHDNIF\I-OUYJ/@_P ?7OPU@\'V/Q:U
MC2?'4>FZ?8S_ !8B\*^$;K6[FZMI(3?:J?"]UIS^$8+K4XDFA>*/3/L=GY_G
M6D"/''M]7XZ<?3C^5&%YX'OP.W3/T_2OHLRXMS_-Z.38?,<7A,31X?IPHY11
M>3Y)0I8/#PJSK_5E3PV4T%7PDL14J8BIA<5+%4*N(JUJ]6-2M6JU*GPV2^''
M"/#V)XDQN3X',,'B^+I3J\1XG_63BK%5\SQ-2A'"?79U<=Q%C)8;,*>$ITL'
MA\PP"P.-PN#H8?"8:M0P^'H4J7Y#V_\ P2?TNS^([?&"U_:<^+EK\3/^$FN?
M&1\8V^@^"H=2_P"$FO+B:ZNM5\J+35L#)<S3S^?;&T^PSQ32V\ELUO(T1^H/
MC;^Q-X"_:/\ AGX4\'_&KQ)KWBWQYX.M+VWTGXRV-CH/ASQFTU_*6NC=:9I6
MG)X9N--NE2T6\T5]--E)+9QWMNMI>M).?MDX[X_'_/TI,+GHN?H,_P">?UKW
M\=XK>(F98_),UQ7%.,_M3AM1AD698;#97@,?E="%%T(X/"XS+\JP=>.7^Q;I
M2RZI*OE\J?NO!GR>4_1]\',DRKBC(LOX%RU9)QJZE3BO)\;C\^S7*\^Q-6O'
M$SQ^/R_-L_S'"SS58B*KPSBE##YO3JQ4Z>90;DW^8/@W_@GW\1]%\/1?#?Q3
M^VK\</$?P:B@_LS_ (5YHUO8>%;J]\/@;)/#=SXP_M#6]?M-%GMQ]BN++2)-
M.B^Q/+:VJVL,@5?J[XJ?LQ_#'XH_ &X_9S?37\(^ 8]#T?2/#</AM(89_";^
M&I;6X\.7ND1W4<\$DFF7-G TD=VDJW\;7,5VQ:YDD'TA@<<#CD=.,]Q]:" >
MH!^HS7FYCQ]Q?FF89?FN)SAT<?E>90SG U<MP&4Y/"EG%.<)QS66'R;*LLPU
M?,FZ<5+'8JCBL2X.I3Y_8UJ]&M[62^$'AUD&49KD."X=CB,KSO)*O#.98?.\
MVX@XDJ5^&ZM.I2EP]2Q7$>>YUB\%D:A5DX95E]? X.-6-&OR3Q&&PU;#?GO\
M#/V*?'?P3\)S^&[3]JSXIZN^D^&]8\,_#9+?1O#]AX5^'%MK>H0W]YJ]IX,U
M#^WM/\3ZV'@,=A-XGN=0L-)BN;S^S-/MGFW)PO@K_@G-K'P_^+FK?'+PU^U5
M\4X/B=XCFOY/$GB2Z\'_  XOW\00ZS=6=SK%I?:?=Z)+I8M[^33[0E;2RMVM
M3!%]B,&P*?U""J.@ []!1@>@X&!P.!Z?2N]>*''2Q&?XI9S0C6XHHRPO$$H9
M%PU36:X6<I5*F&Q=./#_ +.5"M7;Q5>E3C2AB,;*6.KNIC.6O'R7X"^%<L%P
MIE\N&\3/"\#XJ&/X3A/BKC:<\BQ]*$:-''8"M+BZ56EC,-A8PP&$Q,I3J83+
M:<,LPJH8#GPT_P U_P!H#_@GI/\ M'?$*R^(GCO]HOXC17/AZ]N)_ 6D:7X7
M\#6EAX%LWU.WU:WL=*E@TN*[OI+6\M+-_P"TM7DO;^X-K#YTK!2I]@^,W[,/
MC3XV_"31/A!XG_:+\=6VC'2)=*^(6J67@[X?+J?Q.87UG?V-SK)&B)'H36,E
MDJF#PR-,@O%9FO!*V*^R,#T'Y48'H/RKE?B)QBZ?#-+^UJ;I\'3=3AB#RG(G
M'):CE&HY8/\ X1=Y5XQQ<_;^WYL=&..=\;&.)7H+P8\.(UN-<2L@KK$>(U".
M&XXK+B+BQ5.):$$Z<:>8S_UF;<88:4\OA]6^IRIY54J93"4<KJU<%/X+^%'[
M'GCOX*_";4OA#\/_ -J3XDZ-H#7T%YX;OAX(^&EWJO@])=2U+4?$5KI,U[H5
MU]HB\27.H*\SZC]JDTM[=9-*:T,\X;D?V<O^"?=Q^S%XRNO%GP]_:(^(LECK
M^H:==^._#&I^%O MQIGC:VTZXO+J*SU&[GTJ74M+9Y+^\!U#1;BRO$%U+M<A
ME"_I%@>@].@Z#H*,#T'Y"M:GB5QM5H<18>KG-.='BVK[?B:#R?A]/.ZR?/&K
MCIQR-5*E2G6_VJE.,Z;I8QRQE+V>+G/$2YL/X&^&&%Q'!V)H<.5Z57P]H_5^
M"91XDXPMPS0:E"='*:<N*94</2JT)2P=>DZ->&(R[ERRO[;+8QP4/SO_ &G?
MV M!^/WQ0\-?''PE\4/$_P &/B]X;ATJW7Q7X=L8-8@O5T.=Y=%OGLI;[2[J
MRUK38YI;2.^M-26WNK(I:WUE<)&A'+_%S_@F[I7QO\,^#-+^)?Q[^)_B_P 5
M:%K\^JZ_\0-?ATF\US5]'DTRYL%\*^%]&C%IX6\"Z.MU-%J-P]CHVI:AJ5U
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M?/OAC^VM^V%\9/AFWQ=^&W['/A/Q/X-,^KV]N+;XWV]KXAU.70[B2TU*/2]
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M?!C/ ?AGJFES^)O$WBG4Q>16">&/!]CIEI;:CJWB^2\N((4\/7.DV%P\$O\
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M#XX?L2^!M.^+OPW\*^.K71?'?Q(;19=>T]9[O3EN?$3R7+:9J430:CI\=Q(
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M$=:U*/6-5&JZ=J7A>ZTZ47FIQ1WK>5;0-;S+FT:W!8'[-^-WPDU[XQ?#^X\
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MT<15Q>(QF<RP]2KAL1^(G_!*_P #^'/BEXJ^-?A3QA\1OB[X(\?E- \1K:^
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MRRNE+A_&5L3# 4)9A&$L/1I86I7JN=+Y'_;O@^T?\%+?V/("H=9#\)@4R1N
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MUG5-0>*S^WVVGV6G37"75Q%^UFL?LX,6=K"7*Y.%/*^V>H/;)X'4'%?QU?\
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MN4I/4_1<FX.P^#K+&8^4<7B5-U:<'"*I49RM>R:?,TUH]$K*PU(DC0(BA54
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
